Lanicemine Hydrochloride

N/A

Report date: 2025/12/02 15:16:03
NME

Base Information

Drug NameLanicemine Hydrochloride
Drug Alias Namelanicemina拉尼西明拉尼西明盐酸盐laniceminumARR-15896AR +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorDepression +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSlovakiaSouth Africa +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca PlcNational Institute Of Mental Health (Nimh)
Active IndicationsN/A
Inactive IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorDepression +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank